Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
NEUP
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C
Value
B
Factor Score
3.3
/ 5.0
Growth
D+
Factor Score
1.8
/ 5.0
Profitability
C+
Factor Score
2.8
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.0
EV / EBITDA
0.7
Rev Growth YoY
N/A
Gross Margin
N/M
Price Return 3M
-33.3%
Price Return 12M
-47.2%
Catalyst Signal
0.00
Market Cap
$14.0M
TTM Revenue
$1.2M
Price / Sales
11.9
ROE
-61.7%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B (3.3) | D+ (1.8) | C+ (2.8) | D+ (1.7) | C+ (2.6) | C (2.5) |
| 2026-11-06 | B (3.4) | D+ (1.8) | C+ (2.8) | C- (1.9) | C+ (2.7) | C+ (2.5) |
| 2026-10-30 | B (3.3) | D+ (1.7) | C+ (2.8) | C- (1.9) | C+ (2.7) | C (2.5) |
| 2026-10-23 | B (3.3) | D+ (1.7) | C+ (2.8) | C (2.2) | C+ (2.6) | C+ (2.5) |
| 2026-10-16 | B (3.3) | D+ (1.7) | C+ (2.8) | C (2.2) | C+ (2.6) | C+ (2.5) |
Page
1
of
4